The SISAQOL-IMI consortium, co-led by the European Organization for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has published a paper in The Lancet Oncology outlining how ...

Access to patient-reported outcome (PRO) data significantly improved providers' consistency in assessing adverse events in patients with cancer, with the greatest improvements observed for ...

A large multinational clinical trial has found that giving healthcare providers access to European Organisation for Research and Treatment of Cancer (EORTC) patient-reported outcome (PRO) data ...

Annual Meeting, Boehringer Ingelheim will present new data from across its robust oncology clinical development program. Key data includes patient-reported outcomes with HERNEXEOS® (zongertinib ...

The center-specific survival analysis annually assigns all hematopoietic cell transplantation (HCT) centers in the United States a +1, −1, or 0 score for observed outcomes that are above, below, or ...

Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 ...

New partnerships and in-state capabilities are reducing the need for cross-market travel while expanding access to CAR T-cell ...

Please provide your email address to receive an email when new articles are posted on . Patients who reported more fatigue prior to cancer treatment had significantly greater odds of having serious ...

Prospective clinical trials needed to validate the findings ...